ArticleEuropean journal of neurology2025
The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- The Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesProgressive supranuclear paralysis (PSP) is an atypical parkinsonian disorder associated with oculomotor features, motor disturbances, along with cognitive problems and neuropsychiatric symptoms. Quality of life (QoL) is often assessed in relation to the motor symptoms. Our aim was to investigate the impact of neuropsychiatric symptoms on QoL.
methodsWe used data from 40 patients meeting criteria for probable PSP from the Rossy PSP Centre. Motor and neuropsychiatric symptoms, cognition, functionality, disease severity, and quality of life were examined using validated scales. We performed a linear regression model using multiple imputations with chained equations with 500 sets.
resultsWe found that lower quality of life scores were related to higher anxiety and depression and the interaction between these two. There was a decrease in the quality of life of -3.7 points (95% CI: -6.1 to -1.1) for every one point of increase on the depression scale; there was a decrease in the quality of life scale of -4.3 points for each point of increase on the depression score (95% CI: -7.8 to -0.8). The fully adjusted linear model showed that motor scores, cognition, and other neuropsychiatric symptoms were not associated with quality of life.
conclusionWe found that both anxiety and depression significantly impacted quality of life. Given the prevalence of non-motor manifestations in PSP, these results emphasize the importance of comprehensive evaluations to better capture the multi-faceted impairments seen in PSP that have a meaningful impact on the patient's life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.